Impact of temporalis muscle thickness in elderly patients with newly diagnosed glioblastoma treated with radio or radio-chemotherapy.

Elderly patients Elderly patients with glioblastoma Geriatric oncology sarcopenia Glioblastoma Glioblastoma biomarkers Radiotherapy Temporalis thickness

Journal

La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 26 08 2021
accepted: 30 06 2022
pubmed: 19 7 2022
medline: 6 8 2022
entrez: 18 7 2022
Statut: ppublish

Résumé

There is an unmet need for new biomarkers able to predict both the outcomes of up-front therapy and the compliance of elderly patients diagnosed with glioblastoma. For this purpose, temporal muscle thickness is a promising tool to be investigated. Data from 52 glioblastoma patients older than 65 years, treated with post-operative radio or radio-chemotherapy and referred to Pisa University Hospital, were retrieved. The thickness of temporal muscle (TMT) was divided into quartiles and correlated with overall survival (Our primary endpoint). Survival curves were calculated using Kaplan-Meier method, and log-rank test was used to evaluate the differences between curves. Patients in the lower quartile of TMT, with TMT thinner than 7 mm, have survived longer; both univariate and multivariate analyses showed a statistically significant correlation between TMT and overall survival (P = 0.012 and P = 0.003, respectively). Future prospective and more extensive studies focused on elderly glioblastoma patients are needed to confirm the role of TMT as prognostic value on OS and to help explaining this association.

Sections du résumé

BACKGROUND BACKGROUND
There is an unmet need for new biomarkers able to predict both the outcomes of up-front therapy and the compliance of elderly patients diagnosed with glioblastoma. For this purpose, temporal muscle thickness is a promising tool to be investigated.
METHODS METHODS
Data from 52 glioblastoma patients older than 65 years, treated with post-operative radio or radio-chemotherapy and referred to Pisa University Hospital, were retrieved. The thickness of temporal muscle (TMT) was divided into quartiles and correlated with overall survival (Our primary endpoint). Survival curves were calculated using Kaplan-Meier method, and log-rank test was used to evaluate the differences between curves.
RESULTS RESULTS
Patients in the lower quartile of TMT, with TMT thinner than 7 mm, have survived longer; both univariate and multivariate analyses showed a statistically significant correlation between TMT and overall survival (P = 0.012 and P = 0.003, respectively).
CONCLUSION CONCLUSIONS
Future prospective and more extensive studies focused on elderly glioblastoma patients are needed to confirm the role of TMT as prognostic value on OS and to help explaining this association.

Identifiants

pubmed: 35849309
doi: 10.1007/s11547-022-01524-2
pii: 10.1007/s11547-022-01524-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

919-924

Informations de copyright

© 2022. Italian Society of Medical Radiology.

Références

Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21(Suppl 5):v1–v100. https://doi.org/10.1093/neuonc/noz150
doi: 10.1093/neuonc/noz150 pubmed: 31675094 pmcid: 6823730
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2020) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-020-00447-z
doi: 10.1038/s41571-020-00447-z pubmed: 33293629 pmcid: 7904519
Minniti G, Lombardi G, Paolini S (2019) Glioblastoma in Elderly patients: current management and future perspectives. Cancers (Basel) 11 (3). Doi: https://doi.org/10.3390/cancers11030336
Pasqualetti F, Ferrazza P, Cocuzza P, Fatigante L, Pasqualetti G, Fabbrini MG, Monzani F (2014) Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience Anticancer Res 34(8):4281–4285
pubmed: 25075059
Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall’Agata M, Eoli M, Della Puppa A, Pambuku A, D’Avella D, Berti F, Rudà R, Zagonel V (2015) Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). J Neurooncol 125(2):359–367. https://doi.org/10.1007/s11060-015-1923-x
doi: 10.1007/s11060-015-1923-x pubmed: 26423801
Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG (1994) A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 29(4):835–839. https://doi.org/10.1016/0360-3016(94)90573-8
doi: 10.1016/0360-3016(94)90573-8 pubmed: 8040031
Piccirillo SGM, Alonso MM, Pasqualetti F (2018) Basic and Translational Advances in Glioblastoma. Biomed Res Int 2018:1820345. https://doi.org/10.1155/2018/1820345
doi: 10.1155/2018/1820345 pubmed: 29780818 pmcid: 5892300
Penna F, Ballarò R, Beltrà M, De Lucia S, García Castillo L, Costelli P (2019) The skeletal muscle as an active player against cancer cachexia. Front Physiol 10:41. https://doi.org/10.3389/fphys.2019.00041
doi: 10.3389/fphys.2019.00041 pubmed: 30833900 pmcid: 6387914
Lee HS, Kim SY, Chung MJ, Park JY, Bang S, Park SW, Song SY (2019) Skeletal muscle mass predicts poor prognosis in patients with advanced pancreatic cancer undergoing second-line FOLFIRINOX chemotherapy. Nutr Cancer 71(7):1100–1107. https://doi.org/10.1080/01635581.2019.1597906
doi: 10.1080/01635581.2019.1597906 pubmed: 30955349
Furtner J, Genbrugge E, Gorlia T, Bendszus M, Nowosielski M, Golfinopoulos V, Weller M, van den Bent MJ, Wick W, Preusser M (2019) Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro Oncol 21(12):1587–1594. https://doi.org/10.1093/neuonc/noz131
doi: 10.1093/neuonc/noz131 pubmed: 31369680 pmcid: 6917403
Muglia R, Simonelli M, Pessina F, Morenghi E, Navarria P, Persico P, Lorenzi E, Dipasquale A, Grimaldi M, Scorsetti M, Santoro A, Politi LS (2021) Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. Eur Radiol 31(6):4079–4086. https://doi.org/10.1007/s00330-020-07471-8
doi: 10.1007/s00330-020-07471-8 pubmed: 33201284
Liu F, Xing D, Zha Y, Wang L, Dong W, Li L, Gong W, Hu L (2020) Predictive Value of Temporal Muscle Thickness Measurements on Cranial Magnetic Resonance Images in the Prognosis of Patients With Primary Glioblastoma. Front Neurol 11:523292. https://doi.org/10.3389/fneur.2020.523292
doi: 10.3389/fneur.2020.523292 pubmed: 33304303 pmcid: 7693652
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. https://doi.org/10.1200/JCO.2009.26.3541
doi: 10.1200/JCO.2009.26.3541 pubmed: 20231676
Hsieh Kristin HM (2019) Temporalis muscle width as a measure of sarcopenia correlates with overall survival in patients with newly diagnosed glioblastoma. J Radiat Oncol 8:8.
Yesil Cinkir H, Colakoglu Er H (2020) Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme? Asia Pac J Clin Oncol 16(5):e223–e227. https://doi.org/10.1111/ajco.13369
doi: 10.1111/ajco.13369 pubmed: 32762134
Furtner J, Weller M, Weber M, Gorlia T, Nabors B, Reardon DA, Tonn JC, Stupp R, Preusser M, Group EBT (2021) temporal muscle thickness as a prognostic marker in patients with newly diagnosed glioblastoma: translational imaging analysis of the CENTRIC EORTC 26071–22072 and CORE Trials. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-1987
doi: 10.1158/1078-0432.CCR-21-1987
Katsuki M, Narita N, Sasaki K, Sato Y, Suzuki Y, Mashiyama S, Tominaga T (2021) Standard values for temporal muscle thickness in the Japanese population who undergo brain check-up by magnetic resonance imaging. Surg Neurol Int 12:67. https://doi.org/10.25259/SNI_3_2021
doi: 10.25259/SNI_3_2021 pubmed: 33767871 pmcid: 7982108

Auteurs

Francesco Pasqualetti (F)

Oncology Department, Oxford University, Roosevelt Drive, Oxford, OX3 7DQ, UK. francesco.pasqualetti@oncology.ox.ac.uk.
Radiation Oncology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy. francesco.pasqualetti@oncology.ox.ac.uk.

Michela Gabelloni (M)

Radiology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Alessandra Gonnelli (A)

Radiation Oncology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Lorenzo Faggioni (L)

Radiology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Martina Cantarella (M)

Radiation Oncology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Sabrina Montrone (S)

Radiation Oncology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Giovanni Gadducci (G)

Radiation Oncology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Noemi Giannini (N)

Radiation Oncology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Nicola Montemurro (N)

Neurosurgery Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Roberto Mattioni (R)

Radiation Oncology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Paolo Perrini (P)

Neurosurgery Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Riccardo Morganti (R)

Statistic Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Mirco Cosottini (M)

Neuroradiology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Emanuele Neri (E)

Radiology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Fabiola Paiar (F)

Radiation Oncology Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56123, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH